Acute Kidney Injury Market Research Report 2032

Acute Kidney Injury Market Insights, Epidemiology and Market Forecast- 2032' report delivers an in-depth understanding of the Acute Kidney Injury, historical and forecasted epidemiology as well as the Acute Kidney Injury market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), And Japan.

Acute Kidney Injury Epidemiology

The Acute Kidney Injury epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Population of Acute Kidney Injury (AKI) in Hospitalized Patients, Mortality Adjusted Incident Population of AKI in Hospitalized Patients, Stage-specific Incident Population of AKI, and Age-specific Incident Population of AKI in the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan.

Key Findings of Acute Kidney Injury Epidemiology:

·         In 2020, the incident population of AKI in the 7MM was 10,907,615. The mortality adjusted incident population of AKI in hospitalized patients in the seven major market, was estimated to be 6,544,569 in 2020.

·         The United States encompasses the highest incident population of AKI in hospitalized patients, compared to EU5 and Japan. In the United States, mortality adjusted incident population of AKI in hospitalized patients accounted for 2,231,147 in 2020.

·         In 2020, in the United States, there were 1,584,114, 401,606, and 245,426 cases of stage I, stage II, and stage III AKI respectively.

·         In the US, the age group of 60-84 accounted for the highest cases in 2020, followed by 85+ years. In contrast, the least cases were found in the age group of 18-59.

·         In 2020, there were 312,361, 1,004,016, and 914,770 cases, for the age groups 18-59 years, 60-84 years, and 85+ years, respectively.

·         Epidemiology assessed for Acute Kidney Injury showed that Germany accounted for the highest mortality-adjusted incident population of AKI in hospitalized patients in EU5, followed by the UK in 2020.

·         The number of total mortality adjusted incidence of AKI in hospitalized patients is anticipated to be 906,731, 544,235, 506,725, 235,769 and 796,443 in 2020, for Germany, France, Italy, Spain, and UK, respectively.

·         Epidemiology assessed for AKI showed that Japan, in 2020, accounted for the second-highest mortality-adjusted incident population of AKI in hospitalized patients in 7MM, about 1,323,519 cases.

Request for Sample Page: https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market

View Report: https://www.delveinsight.com/report-store/acute-kidney-injury-aki-market

Key Findings of Acute Kidney Injury Market Outlook

·         The total Acute Kidney Injury market size is calculated by including the market size of both emerging and current therapies. The total Acute Kidney Injury market size in the 7MM was estimated to be USD 5,436 million in 2020 during the study period 2018-2030.

·         In the 7MM, most of the share in the current market was captured by the United States, which was USD 2,786.7 million, while the second-highest revenue generator was Japan, taking nearly USD 840.4 million in its box, in 2020.The dynamics are anticipated to change during the forecast period, i.e., 2021-2030, owing to the launch of more effective drugs with clinically improved outcomes.

·         Among the 7MM countries, the US accounts for the largest Acute Kidney Injury market size. The growth of market size for AKI is attributed to emerging therapies. The market size for AKI was USD 2,786.7 million in 2020.

·         Among the EU-5 countries, Germany accounted for the highest market size of AKI in 2020. The market size of AKI in the EU5 was USD 1,809 million in 2020, inclusive of current treatment regimens. The lowest market is estimated to be covered by Spain, which accounts for USD 142.6 million in 2020.

·         The market size for AKI in Japan was calculated to be USD 840.4 million in 2020.

Request for Sample Page: https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market

View Report: https://www.delveinsight.com/report-store/acute-kidney-injury-aki-market

Analyst Comments

·         Since AKI is associated with multiple critical care complications such as cardiac surgery, DGF, sepsis, and many more, no targeted pharmacotherapies have been approved for AKI treatment. Consequently, the treatment solely depends on the existing off-label therapeutic options, such as diuretics, NSAIDs, RRT, etc., which have been used for decades.

·         As there is no therapeutic cure to the disease, the risk of AKI is usually prevented by identifying patients at risk, reviewing medications, and reducing the exposure of patients to nephrotoxic drugs. The current treatment approach for such patients needs to be on the preventive side rather than on the curative side. Therefore, the emerging drugs such as bRESCAP, ANG-3777 for AKI-associated with cardiac surgery, QPI-1002, and Ruconest (Conestat alfa) are aiming to prevent the risk of AKI rather than providing therapeutic support after the cause of AKI.

·         Amongst upcoming emerging therapies, ANG-3777 and teprasiran (QPI-1002) for DGF indication are expected to get approval earlier than AKI-associated with cardiac surgery. ANG-3777 has received the Fast Track and Orphan Drug designation by the US FDA and is planning to submit NDA by 2022 for DGF. QPI-1002, on the other hand, has been granted Orphan Drug designation by the US FDA and EU and is aiming to support NDA submission for the DGF indication. Besides, recAP and bRESCAP are also among the key players in the late phases of development and are expected to enter the market soon.

View Report: https://www.delveinsight.com/report-store/acute-kidney-injury-aki-market

Acute Kidney Injury Companies Mentioned

·         Alloksys

·         Angion Biomedica

·         Quark Pharmaceuticals

·         AM Pharma

·         Astellas Pharma

·         Pharming Technologies

·         Exponential Biotherapies

·         Atox Bio

·         And Many Others

View Report: https://www.delveinsight.com/report-store/acute-kidney-injury-aki-market

Table of Contents:

1. Key Insights

2. Executive Summary of Acute Kidney Injury

3. Competitive Intelligence Analysis for Acute Kidney Injury

4. Acute Kidney Injury: Market Overview at a Glance

5. Acute Kidney Injury: Disease Background and Overview

6. Patient Journey

7. Acute Kidney Injury Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Acute Kidney Injury Treatment

11. Marketed Products

List to be continued in report

12. Emerging Therapies

List to be continued in report

13. Acute Kidney Injury: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Acute Kidney Injury

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Get in touch with our Business executive for Regulatory Analysis, Licensing Services, and Consulting Solutions 

DelveInsight’s Competitive Intelligence Service includes a multidimensional coverage, helping to keep track of competitors and gain traction in the dynamic market by overcoming the challenges and expediting business growth through a strategic and tactical approach.

Other Reports:

Related Blogs:

About Delveinsight: 

DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: info@delveinsight.com

Phone: +19193216187

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com/

Connect With Us at:

LinkedIn | Facebook | Twitter

Comments

Post a Comment

Popular posts from this blog

How Competitive intelligence is transforming the scenario for Biotech firms?

What is Competitive intelligence service? Competitive intelligence ideally means gathering information on rival business in the market, analyse the information and use the information to strategize to yield positive results. Going by the definition, competitive intelligence assembles actionable information from diverse published and unpublished sources, collected efficiently and ethically. So, analysts performing Competitive intelligence for their clienteles present a detailed picture of the marketplace, forthcoming challenges and the ways to face them, even before the can harm the client’s business. What could it mean? Competitive intelligence can often give a wrong idea, as it may misunderstood as a service which can help gain an advantage over the rivals. However, this is not the case. Competitive intelligence is an ethical and legal practise undertaken involving the study of analytical data, analysing the market and optimizing the relevant and realistic strategies t...
Read more

Cervical Intraepithelial Neoplasia Market and Epidemiology 2032 by DelveInsight

DelveInsight's " Cervical Intraepithelial Neoplasia Market Insights, Epidemiology, and Market Forecast-2032 " report delivers an in-depth understanding of Cervical Intraepithelial Neoplasia, historical and forecasted epidemiology as well as the Cervical Intraepithelial Neoplasia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Cervical Intraepithelial Neoplasia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Cervical Intraepithelial Neoplasia market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Cervical Intraepithelial Neoplasia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Cervical Intraepithelial Neoplasia market. Request for a Free Sample Report: Cervic...
Read more

The Need And The Importance Of The Healthcare Reports for the Pharma Companies

Image
It is very important for the hospitals and the other medical institutions to preserve and keep the healthcare reports of all the patients very safe and secure. All the medical records are being kept by almost all of these institutes. As a matter of fact, the healthcare reports are very important for comprehending the medical history of the patient. If he or she suffers from the same ailment once more the previous reports will be absolutely indispensible while treating him or her. Nowadays, with the advancement of technology the manual records are slowly and gradually getting digitalized. It is easier to store and preserve the digital records than the manual and the physical ones.  Choosing The Best And The Most Professional Services For Healthcare Reports: • Rising Pharma Market for You Now In the market there are a host of companies that preserves the healthcare reports of the various patients. All of it is now being done in the digital format due to the adv...
Read more